BioSpecifics Technologies Corp
BioSpecifics Technologies — Investor Presentation (November 2017)
27 slides from BioSpecifics Technologies's investor presentation, Nov 15, 2017
Slide 1: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of: INJECTABLE COLLAGENASE @ —— = @ ‘ BioSpecifics November 2017
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact, including statements regarding
Slide 3: Company Overview (NASDAQ: BSTC)
Company Overview (NASDAQ: BSTC) Originator of collagenase based-therapies Positive clinical results for XIAFLEX reported in 12 indications to date Profitable biopharma company with lean corporate structure Receives revenues from XIAFLEX® milestones, royalties on net sales, mark-up on COGS and sublic
Slide 4: Pipeline
XIAFLEX® Pipeline Dupuyer’ Contacure <r [> Peyronie's Disease ro E> Initiate Phase 3 trials in the coming Callulte endo months following FDA discussions Endo is currently performing a Adhesive Capsulitis endo. commercial review Endo is currently performing a Human Lipoma si endo commercial review Ca
Slide 5: Marketed XIAFLEX Indications
Marketed XIAFLEX Indications: Dupuytren’s Contracture & Peyronie’s Disease
Slide 6: XIAFLEX 3Q 2017 Total Revenues
XIAFLEX 3Q 2017 Total Revenues » Third quarter 2017 total revenues were $52.5M| vs. $47.7M for third quarter 2016, an 10% increase
Slide 7: XIAFLEX Future Growth Opportunities
XIAFLEX Future Growth Opportunities Endo expects high-single to low-double-digit revenue growth for sales in 2017 Sizable opportunity for growth Of the patients diagnosed with Peyronie’s disease, 85-90% are untreated and for Dupuytren’s contracture 75-80% are untreated FUTURE GROWTH INITIATIVES: Bro
Slide 8: Dupuytren's Contracture
XIAFLEX® for Dupuytren’s Contracture Definition & Key Complications Deforming condition of the hand in which one or more fingers contracts toward the palm Limits range of motion and impairs quality of life Affects between 3-9% of adult Caucasians Pre-treatment: Post-treatment: Source: Endo Internati
Slide 9: Peyronie's Disease
XIAFLEX® for Peyronie’s Disease Definition & Key Complications Inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Associated with increased pain, painful erections, palpable plaque, penile deformity and erectile dysfunction Potential loss of self
Slide 10: Pipeline Indications
XIAFLEX® Pipeline Indications ICS TECHNOLOGIES CORP
Slide 11: Uterine Fibroids
XIAFLEX® for Uterine Fibroids Phase 1 Trial Ongoing Benign tumors in the reproductive tract that contain large amounts of collagen Definition & Key Cause pelvic discomfort and pain, decreased fertility, pregnancy Complications complications, increased rate of miscarriage, uterine bleeding, prolonged
Slide 12: Uterine Fibroids: Phase 1 Trial Design
XIAFLEX® for Uterine Fibroids Phase 1 Trial Design Open-label dose escalation Phase 1 study in 15 female subjects treated prior to hysterectomy at the Department of Gynecology & Obstetrics at Johns Hopkins University 3 subjects injected with saline and 12 to receive XIAFLEX Primary endpoint: Assess
Slide 13: Potential Advantages of XIAFLEX
Potential Advantages of XIAFLEX® Injection vs. Major Surgery Shorter, Easier Process 5-10 minutes vs. 2-4 hours for hysterectomy and myomectomy and 1-2 hours for uterine artery embolization No intubation Sedation vs. anesthesia for surgery - Limited Recovery Time “Lost work” costs of $4,500-$30,000
Slide 14: Cellulite
XIAFLEX® for Cellulite OVERVIEW Skin dimpling as a result of collagen fibrous septae, occurring mainly on the buttocks, lower limbs, and abdomen Highly Statistically Significant Affects ~85-98% of post-pubertal Positive Results from Phase females 2b Study Anatomy of Gakuite CCH: 2-Pt Composite Respo
Slide 15: Cellulite: Phase 2b Top-line Data
XIAFLEX® for Cellulite Highly Statistically Significant Top-line Data from Phase 2b Study 375 women with moderate or severe cellulite (18+ years) Up to 3 treatment sessions of 0.84 mg/session or placebo (12 injections per session) with each treatment session occurring 21 days apart Primary endpoint
Slide 16: Adhesive Capsulitis
XIAFLEX® for Adhesive Capsulitis Potential to be Only FDA Approved Nonsurgical Therapy Inflammation and thickening of shoulder capsule due to collagen Limits range of motion of shoulder Common available treatment options are often painful and can require anesthesia Long-term intensive physical thera
Slide 17: Phase 2b Study Results of XIAFLEX in Adhesive Capsulitis
Phase 2b Study Results of XIAFLEX® in Adhesive Capsulitis/Frozen Shoulder Syndrome Phase 2a Results a o | | a | Strong, similar drug effect for key measures including am forward flexion, shoulder abduction, external andinternal ° “eet gene ort ‘peste Ec £ rotation across both Phase 2a and Phase 2b t
Slide 18: Plantar Fibromatosis
XIAFLEX® for Plantar Fibromatosis Definition & Complications ~200,000 patients in the U.S. Pain and disability caused by the thickening of the feet's deep connective tissue Formation of nodules or cords along tendons of the foot Patients often have Dupuytren’s disease, Ack Peyronie’s disease and adh
Slide 19: Human Lipomas
XIAFLEX® for Human Lipomas Definition Potential to be Only FDA-Approved Pharmaceutical Therapy U.S. Market Opportunity Phase 2 Trial Design Encapsulated deposits of benign fat, often detected as bulges under the skin No FDA-approved pharmaceutical therapies available Offers an alternative to patient
Slide 20: Positive Top-Line Phase 2 Study Results
Positive Top-Line Phase 2 Study Results Single 0.58 mg Injection of XIAFLEX Primary endpoint: 81.3% reduction in visible surface area for XIAFLEX vs. 2.1% increase for placebo; 83.4% difference in favor of XIAFLEX (p<0.0001) 89.5% responder rate (showed a 250% decrease in lipoma visible surface area
Slide 21: Lateral Hip Fat
XIAFLEX® for Lateral Hip Fat Definition & Complications Similar prevalence to cellulite » Fat accumulation is common among woman particularly as they age Often very difficult to improve its appearance through exercise and diet alone Patients frequently avoid exercise and are unable to restrict their
Slide 22: Additional Promising Unlicensed Indications
Additional Promising Unlicensed Indications Capsular Contracture, Breast Hypertrophic Scars & Keloids Dercum’s Disease Knee Arthrofibrosis Urethral Strictures Source: Endo International ple Post-surgical complication that can deform the breast and cause pain Scars that form on the skin at site of in
Slide 23: Endo Partnership for Development and Commercialization of XIAFLEX
Endo Partnership for Development and Commercialization of XIAFLEX® >$126.5M Received as of September 30, 2017 Future Payments Due to BioSpecifics from Endo Endo Opt-in Rights Sublicense Income from Endo Partnerships $126.5M received in licensing, sublicensing, milestone, COGS, and royalty payments a
Slide 24: Strong IP Portfolio
Strong IP Portfolio Dupuytren’s Contracture Biologic Exclusivity until 2022 Drug product composition patent until 2028 Peyronie’s Disease Orphan Drug protection in U.S. until 2020 Drug product composition patent until 2028 Uterine Fibroids Method of use patent until 2034 Patents and Patent Applicati
Slide 25: Consistently Profitable Annually
Consistently Profitable Annually Financial Highlights (unaudited) For the nine months ended 09/30/2017 09/30/2016 Cash and equivalents, and investments $61,302,137 $51,266,414 Income Statement Revenues $20,742,243 $19,630,307 Other income 476,861 238,152 Costs and expenses (7,865,860) (6,915,669) Pr
Slide 26: Anticipated Upcoming Pipeline Milestones
Anticipated Upcoming Pipeline Milestones ENDO: Cosmetic and Other Indications O Initiate Phase 3 clinical trials in coming months following FDA Cellulite discussions 0 Publication of full Phase 2b data Other Indications O Commercial review of additional indications ongoing BIOSPECIFICS: Serious Medi
Slide 27: Innovators in the development & commercialization of injectable collagenase
Innovators in the development & commercialization of INJECTABLE COLLAGENASE i 7 BioS pecifics November 2017
Biospecifics Technologies — Investor Presentation (November 2017) on 6ix